However, a similar trend was not confirmed in the COMBI-AD trial, which enrolled only BRAF-mutated patients and therefore analyzed a significantly higher number of BRAF-mutated patients (870 vs. 440). The gene discussed is BRAF; the disease is Alzheimer disease.